Adicet Stock Today

ACET
 Stock
  

USD 15.40  0.27  1.72%   

Market Performance
6 of 100
Odds Of Distress
Less than 6
Adicet Bio is selling for under 15.40 as of the 14th of August 2022; that is -1.72% down since the beginning of the trading day. The stock's last reported lowest price was 15.23. Adicet Bio has only a 6 % chance of going through financial distress over the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Adicet Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of July 2021 and ending today, the 14th of August 2022. Click here to learn more.
CUSIP
004446100
Fiscal Year End
June
Business Domain
Health Care Equipment & Services
IPO Date
26th of January 2018
Category
Healthcare
Classification
Health Care
ISIN
US0070021086
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. The company has 39.14 M outstanding shares of which 5.29 M shares are presently shorted by private and institutional investors with about 10.27 trading days to cover. More on Adicet Bio

Moving together with Adicet Bio

0.82AIKIAIkido Pharma Earnings Call  TomorrowPairCorr

Moving against Adicet Bio

0.9ALRNAileron Therapeutics Earnings Call  TomorrowPairCorr
0.76ABVCAbvc Biopharma Earnings Call  This WeekPairCorr
0.74AGTCApplied Genetic Tech Fiscal Year End 22nd of September 2022 PairCorr
0.61ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Adicet Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Adicet Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Adicet Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Adicet Bio has very high historical volatility over the last 90 days
Adicet Bio was previously known as ADICET BIO INC and was traded on NASDAQ Exchange under the symbol TORC.
The company reported the previous year's revenue of 38.7 M. Net Loss for the year was (36.06 M) with profit before overhead, payroll, taxes, and interest of 9.73 M.
Adicet Bio currently holds about 277.88 M in cash with (31.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.95.
Adicet Bio has a frail financial position based on the latest SEC disclosures
Over 90.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Sale by Aftab Blake of 6968 shares of Adicet Bio
Older SymbolTORC
New SymbolACETQ
CEO and President and DirectorSalvatore Guccione
Fama & French Classification
Average Analyst Recommendation
Analysts covering Adicet Bio report their recommendations after researching Adicet Bio's financial statements, talking to executives and customers, or listening in on Adicet Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Adicet Bio. The Adicet consensus assessment is calculated by taking the average forecast from all of the analysts covering Adicet Bio.
Strong Buy5 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Adicet Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Adicet Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares33.4 M31 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted33.4 M31 M
Significantly Up
Increasing
Slightly volatile
Total Assets365.7 M338.9 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities32.6 M35.8 M
Significantly Down
Increasing
Slightly volatile
Current Assets304.7 M282.4 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities16.1 M16.3 M
Fairly Down
Increasing
Slightly volatile
Total Debt20 M20.9 M
Sufficiently Down
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.03490.034
Fairly Up
Decreasing
Very volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Adicet Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Adicet Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Adicet Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adicet Bio's financial leverage. It provides some insight into what part of Adicet Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Adicet Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Adicet Bio deploys its capital and how much of that capital is borrowed.
Liquidity
Adicet Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 20.58 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Adicet Bio has a current ratio of 26.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Adicet Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Adicet Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adicet Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adicet to invest in growth at high rates of return. When we think about Adicet Bio's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(52.4 Million)
Adicet Bio (ACET) is traded on NASDAQ Exchange in USA. It is located in 200 Clarendon Street, Floor 6, Boston, MA 02116, United States and employs 86 people. Adicet Bio was previously known as ADICET BIO INC and was traded on NASDAQ Exchange under the symbol TORC. Adicet Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 602.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adicet Bio's market, we take the total number of its shares issued and multiply it by Adicet Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Adicet Bio conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 39.14 M outstanding shares of which 5.29 M shares are presently shorted by private and institutional investors with about 10.27 trading days to cover. Adicet Bio currently holds about 277.88 M in cash with (31.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.95.
Check Adicet Bio Probability Of Bankruptcy
Ownership
Adicet Bio holds a total of thirty-nine million one hundred fourty thousand outstanding shares. The majority of Adicet Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adicet Bio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adicet Bio. Please pay attention to any change in the institutional holdings of Adicet Bio as this could imply that something significant has changed or about to change at the company. Also note that nearly three hundred ninety-one thousand four hundred invesors are currently shorting Adicet Bio expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Adicet Ownership Details

Adicet Stock Price Odds Analysis

What are Adicet Bio's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Adicet Bio jumping above the current price in 90 days from now is about 34.06%. The Adicet Bio probability density function shows the probability of Adicet Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.1194. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Adicet Bio will likely underperform. Additionally, the company has an alpha of 0.3287, implying that it can generate a 0.33 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 15.4HorizonTargetOdds Above 15.4
65.84%90 days
 15.40 
34.06%
Based on a normal probability distribution, the odds of Adicet Bio to move above the current price in 90 days from now is about 34.06 (This Adicet Bio probability density function shows the probability of Adicet Stock to fall within a particular range of prices over 90 days) .

Adicet Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Adicet Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adicet Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adicet Bio's value.
InstituionSecurity TypeTotal SharesValue
Cowen And Company LlcCommon Shares2.4 M35.7 M
Blackrock IncCommon Shares1.8 M27 M
View Adicet Bio Diagnostics

Adicet Bio Historical Income Statement

Adicet Bio Income Statement is one of the three primary financial statements used for reporting Adicet's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Adicet Bio revenue and expense. Adicet Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Adicet Bio Gross Profit is comparatively stable at the moment as compared to the past year. Adicet Bio reported Gross Profit of 9.73 Million in 2021. Revenues is likely to gain to about 10.4 M in 2022, whereas Earning Before Interest and Taxes EBIT is likely to drop (63.6 M) in 2022. View More Fundamentals

Adicet Stock Against Markets

Picking the right benchmark for Adicet Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Adicet Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Adicet Bio is critical whether you are bullish or bearish towards Adicet Bio at a given time.

Similar Equity Warning - ACET

Adicet Bio was forked

The entity Adicet Bio with a symbol ACET was recently forked. You can potentially use ACETO CORP with a symbol ACETQ from now on.

Adicet Bio Corporate Directors

Adicet Bio corporate directors refer to members of an Adicet Bio board of directors. The board of directors generally takes responsibility for the Adicet Bio's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Adicet Bio's board members must vote for the resolution. The Adicet Bio board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Hans Noetzli - Lead Independent DirectorProfile
Natasha Giordano - DirectorProfile
Alan Levin - Independent DirectorProfile
Daniel Yarosh - DirectorProfile

Invested in Adicet Bio?

You need to understand the risk of investing before taking a position in Adicet Bio. The danger of trading Adicet Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adicet Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adicet Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adicet Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Adicet Bio information on this page should be used as a complementary analysis to other Adicet Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Adicet Stock analysis

When running Adicet Bio price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Adicet Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
616.5 M
Quarterly Revenue Growth YOY
0.011
Return On Assets
-0.1
Return On Equity
-0.18
The market value of Adicet Bio is measured differently than its book value, which is the value of Adicet that is recorded on the company's balance sheet. Investors also form their own opinion of Adicet Bio's value that differs from its market value or its book value, called intrinsic value, which is Adicet Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adicet Bio's market value can be influenced by many factors that don't directly affect Adicet Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adicet Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Adicet Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adicet Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.